224 related articles for article (PubMed ID: 22750997)
1. Palifermin is efficacious in recipients of TBI-based but not chemotherapy-based allogeneic hematopoietic stem cell transplants.
Goldberg JD; Zheng J; Castro-Malaspina H; Jakubowski AA; Heller G; van den Brink MR; Perales MA
Bone Marrow Transplant; 2013 Jan; 48(1):99-104. PubMed ID: 22750997
[TBL] [Abstract][Full Text] [Related]
2. Pharmacoeconomic analysis of palifermin to prevent mucositis among patients undergoing autologous hematopoietic stem cell transplantation.
Nooka AK; Johnson HR; Kaufman JL; Flowers CR; Langston A; Steuer C; Graiser M; Ali Z; Shah NN; Rangaraju S; Nickleach D; Gao J; Lonial S; Waller EK
Biol Blood Marrow Transplant; 2014 Jun; 20(6):852-857. PubMed ID: 24607557
[TBL] [Abstract][Full Text] [Related]
3. Palifermin for prevention of oral mucositis in allogeneic hematopoietic stem cell transplantation: a single-institution retrospective evaluation.
Nguyen DT; Shayani S; Palmer J; Dagis A; Forman SJ; Epstein J; Spielberger R
Support Care Cancer; 2015 Nov; 23(11):3141-7. PubMed ID: 25791390
[TBL] [Abstract][Full Text] [Related]
4. Phase 1/2 randomized, placebo-control trial of palifermin to prevent graft-versus-host disease (GVHD) after allogeneic hematopoietic stem cell transplantation (HSCT).
Blazar BR; Weisdorf DJ; Defor T; Goldman A; Braun T; Silver S; Ferrara JL
Blood; 2006 Nov; 108(9):3216-22. PubMed ID: 16835378
[TBL] [Abstract][Full Text] [Related]
5. Palifermin in children undergoing autologous stem cell transplantation: a matched-pair analysis.
Czyzewski K; Debski R; Krenska A; Wysocki M; Styczynski J
Anticancer Res; 2014 Dec; 34(12):7379-82. PubMed ID: 25503176
[TBL] [Abstract][Full Text] [Related]
6. Impact of palifermin on incidence of oral mucositis and healthcare utilization in children undergoing autologous hematopoietic stem cell transplantation for malignant diseases.
Vitale KM; Violago L; Cofnas P; Bishop J; Jin Z; Bhatia M; Kung AL; George D; Garvin J; Satwani P
Pediatr Transplant; 2014 Mar; 18(2):211-6. PubMed ID: 24823628
[TBL] [Abstract][Full Text] [Related]
7. CD34+ selection and the severity of oropharyngeal mucositis in total body irradiation-based allogeneic stem cell transplantation.
Anand A; Anandi P; Jain NA; Lu K; Dunavin N; Hourigan CS; Le RQ; Chokshi PD; Ito S; Stroncek DF; Sabatino M; Barrett AJ; Battiwalla M
Support Care Cancer; 2016 Feb; 24(2):815-822. PubMed ID: 26190358
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and effects of palifermin for the treatment of oral mucositis in patients affected by acute lymphoblastic leukemia.
Lucchese A; Matarese G; Ghislanzoni LH; Gastaldi G; Manuelli M; Gherlone E
Leuk Lymphoma; 2016; 57(4):820-7. PubMed ID: 26428409
[TBL] [Abstract][Full Text] [Related]
9. Reliability and efficacy of palifermin in prevention and management of oral mucositis in patients with acute lymphoblastic leukemia: a randomized, double-blind controlled clinical trial.
Lucchese A; Matarese G; Manuelli M; Ciuffreda C; Bassani L; Isola G; Cordasco G; Gherlone E
Minerva Stomatol; 2016 Feb; 65(1):43-50. PubMed ID: 26862696
[TBL] [Abstract][Full Text] [Related]
10. The influence of palifermin (Kepivance) on oral mucositis and acute graft versus host disease in patients with hematological diseases undergoing hematopoietic stem cell transplant.
Nasilowska-Adamska B; Rzepecki P; Manko J; Czyz A; Markiewicz M; Federowicz I; Tomaszewska A; Piatkowska-Jakubas B; Wrzesien-Kus A; Bieniaszewska M; Duda D; Szydlo R; Halaburda K; Szczepinski A; Lange A; Hellman A; Robak T; Skotnicki A; Jedrzejczak WW; Walewski J; Holowiecki J; Komarnicki M; Dmoszynska A; Warzocha K; Marianska B
Bone Marrow Transplant; 2007 Nov; 40(10):983-8. PubMed ID: 17846600
[TBL] [Abstract][Full Text] [Related]
11. Palifermin for prevention of oral mucositis after haematopoietic stem cell transplantation- single centre experience.
Rzepecki P; Sarosiek T; Barzal J; Oborska S; Nurzynski P; Wasko A; Szczylik C
J BUON; 2007; 12(4):477-82. PubMed ID: 18067205
[TBL] [Abstract][Full Text] [Related]
12. Palifermin reduces incidence and severity of oral mucositis in allogeneic stem-cell transplant recipients.
Langner S; Staber P; Schub N; Gramatzki M; Grothe W; Behre G; Rabitsch W; Urban C; Linkesch W; Neumeister P
Bone Marrow Transplant; 2008 Aug; 42(4):275-9. PubMed ID: 18500368
[TBL] [Abstract][Full Text] [Related]
13. Palifermin reduces patient-reported mouth and throat soreness and improves patient functioning in the hematopoietic stem-cell transplantation setting.
Stiff PJ; Emmanouilides C; Bensinger WI; Gentile T; Blazar B; Shea TC; Lu J; Isitt J; Cesano A; Spielberger R
J Clin Oncol; 2006 Nov; 24(33):5186-93. PubMed ID: 16391299
[TBL] [Abstract][Full Text] [Related]
14. Palifermin for oral mucositis after intensive therapy for hematologic cancers.
Spielberger R; Stiff P; Bensinger W; Gentile T; Weisdorf D; Kewalramani T; Shea T; Yanovich S; Hansen K; Noga S; McCarty J; LeMaistre CF; Sung EC; Blazar BR; Elhardt D; Chen MG; Emmanouilides C
N Engl J Med; 2004 Dec; 351(25):2590-8. PubMed ID: 15602019
[TBL] [Abstract][Full Text] [Related]
15. Recombinant human keratinocyte growth factor palifermin reduces oral mucositis and improves patient outcomes after stem cell transplant.
Beaven AW; Shea TC
Drugs Today (Barc); 2007 Jul; 43(7):461-73. PubMed ID: 17728847
[TBL] [Abstract][Full Text] [Related]
16. Palifermin does not influence the incidence and severity of GvHD nor long-term survival of patients with hematological diseases undergoing HSCT.
Nasilowska-Adamska B; Szydlo R; Rzepecki P; Czyz A; Tomaszewska A; Markiewicz M; Torosian T; Bieniaszewska M; Hellman A; Jedrzejczak WW; Holowiecki J; Komarnicki M; Warzocha K; Marianska B
Ann Transplant; 2011; 16(4):47-54. PubMed ID: 22210421
[TBL] [Abstract][Full Text] [Related]
17. Palifermin improves severe mucositis, swallowing problems, nutrition impact symptoms, and length of stay in patients undergoing hematopoietic stem cell transplantation.
Horsley P; Bauer JD; Mazkowiack R; Gardner R; Bashford J
Support Care Cancer; 2007 Jan; 15(1):105-9. PubMed ID: 16896881
[TBL] [Abstract][Full Text] [Related]
18. Retrospective Evaluation of Palifermin Use in Nonhematopoietic Stem Cell Transplant Pediatric Patients.
Liu D; Seyboth B; Mathew S; Gilheeney SW; Chou AJ; Drill E; Kobos R
J Pediatr Hematol Oncol; 2017 May; 39(4):e177-e182. PubMed ID: 28234746
[TBL] [Abstract][Full Text] [Related]
19. Palifermin: role in the prevention of chemotherapy- and radiation-induced mucositis.
McDonnell AM; Lenz KL
Ann Pharmacother; 2007 Jan; 41(1):86-94. PubMed ID: 17190850
[TBL] [Abstract][Full Text] [Related]
20. Palifermin for oral mucositis in the high-dose chemotherapy and stem cell transplant setting: the Royal Adelaide Hospital Cancer Centre experience.
Keefe D; Lees J; Horvath N
Support Care Cancer; 2006 Jun; 14(6):580-2. PubMed ID: 16775651
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
